<- Go Home

Mayne Pharma Group Limited

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Market Cap

AUD 422.5M

Volume

200.2K

Cash and Equivalents

AUD 53.7M

EBITDA

AUD 48.1M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

AUD 243.9M

Profit Margin

58.97%

52 Week High

AUD 7.31

52 Week Low

AUD 3.74

Dividend

N/A

Price / Book Value

0.95

Price / Earnings

-3.47

Price / Tangible Book Value

-3.25

Enterprise Value

AUD 337.4M

Enterprise Value / EBITDA

6.50

Operating Income

-AUD 11.1M

Return on Equity

23.75%

Return on Assets

-0.61

Cash and Short Term Investments

AUD 124.9M

Debt

AUD 39.9M

Equity

AUD 446.2M

Revenue

AUD 413.5M

Unlevered FCF

AUD 42.2M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches